Introduction
Jemperli, the brand name for dostarlimab (US suffix: dostarlimab-gxly), is an anti-PD-1 immunotherapy at the centre of GSK plc's (LSE:GSK) oncology ambitions in endometrial cancer. It works by releasing a brake on the immune system, and it is now approved across two distinct settings in the UK, EU and US.
In the first setting it is approved as monotherapy for pre-treated recurrent or advanced disease that is mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H). In the second, it is approved in combination with platinum-containing chemotherapy for first-line primary advanced or recurrent disease, a combination indication that has been expanded to an all-comer population, irrespective of biomarker status, in all three jurisdictions.
This all-comer expansion materially broadens the treatable population and is the strategic thread of GSK's endometrial-cancer approach. This article examines what Jemperli is, how it works, exactly which indications are approved and where, why biomarkers matter, its portfolio importance, its competitors and what investors may wish to monitor.
What is Jemperli?
Jemperli is the brand name for dostarlimab, a humanised IgG4 monoclonal antibody directed against the programmed cell death protein-1 (PD-1) receptor. In the United States the active substance carries the suffix dostarlimab-gxly. It is administered as an intravenous infusion.
The medicine is a direct GSK product. Dostarlimab was originally discovered by AnaptysBio and licensed to TESARO; GSK acquired TESARO in January 2019, bringing dostarlimab into its oncology portfolio. It is not a joint venture in the mould of ViiV Healthcare or Alexion; it sits wholly within the GSK group.
In Great Britain the marketing authorisation is held by GlaxoSmithKline (UK) Limited, which the electronic medicines compendium (emc) lists as the authorisation holder for product 12669. A live UK marketing authorisation confirms that a regulatory product file exists and that specified indications are approved; a substance appearing in a regulatory index is not, by itself, evidence of a new approval, ownership change, launch or commercial success. The indications summarised below are drawn from the current approved product information.
How does dostarlimab work?
According to the approved product information, dostarlimab is an anti-PD-1 blocking antibody. It binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2.
PD-1 is an inhibitory checkpoint that tumours can exploit to dampen the immune response and evade detection. By blocking that interaction, dostarlimab is intended to release PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.
This mechanism places dostarlimab in the same broad immuno-oncology class as several established checkpoint inhibitors. As with other agents in the class, immune activation can be associated with immune-related adverse events, and clinicians manage treatment in line with the approved product information. Efficacy and safety outcomes vary by tumour type, line of therapy and, importantly in endometrial cancer, biomarker status.
Which endometrial-cancer indications are approved?
The approvals span two settings, and the precise wording differs by jurisdiction. In the UK, per the emc Summary of Product Characteristics last revised 25 February 2026, Jemperli is approved as monotherapy for adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen (original MHRA Great Britain approval October 2023). It is also approved in combination with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer in patients who are candidates for systemic therapy, as an all-comer indication not restricted to dMMR/MSI-H.
In the EU, the European Commission first approved dostarlimab monotherapy for dMMR/MSI-H recurrent or advanced endometrial cancer on 21 April 2021, described as the first anti-PD-1 approved for this setting in Europe. The first-line combination with carboplatin and paclitaxel was expanded from a prior dMMR/MSI-H-restricted population to all adult patients by an EC decision announced on 20 January 2025.
In the US, the FDA granted accelerated approval for the dMMR endometrial-cancer monotherapy on 22 April 2021 and converted it to regular approval on 10 February 2023. The combination with carboplatin and paclitaxel, followed by single-agent dostarlimab, was first approved on 31 July 2023 for dMMR/MSI-H disease and expanded to an all-comer population on 1 August 2024. Investors should note that indications must not be merged across jurisdictions; each is defined by its own approved wording.
What role do biomarkers play?
Biomarkers are central to how Jemperli is used, and the mandatory point to verify is which population an indication covers. Mismatch-repair deficiency (dMMR) and microsatellite instability-high (MSI-H) status identify tumours with a high burden of mutations that are typically more responsive to PD-1 blockade. Mismatch-repair proficient (MMRp) or microsatellite stable (MSS) tumours generally respond less well to checkpoint inhibition alone.
This distinction maps directly onto the labels. The monotherapy indication remains restricted to dMMR/MSI-H disease in the UK and EU, and to dMMR disease in the US, in each case in the pre-treated, post-platinum setting. By contrast, the first-line combination-with-chemotherapy indication is now an all-comer indication in the UK, EU and US, covering all biomarker statuses including MMRp/MSS.
A further jurisdictional divergence concerns tissue-agnostic use. The US carries an accelerated-approval indication for dMMR recurrent or advanced solid tumours regardless of tissue of origin (granted 17 August 2021), with continued approval contingent on verification in confirmatory trials. The EU and UK do not carry any tissue-agnostic dMMR solid-tumour indication. Stating the population precisely for each jurisdiction is essential to avoid over-reading the label.
How important is Jemperli to GSK?
GSK positions Jemperli as a key part of its oncology franchise. The company separately discloses Jemperli (dostarlimab) product turnover as a named oncology growth driver in its quarterly and annual financial reporting. No specific revenue figure, market-share percentage or efficacy percentage is asserted here, as none was verified against a primary GSK financial disclosure in this check; where product revenue is disclosed, readers may consult GSK's own results.
The all-comer expansion of the first-line combination indication is strategically significant because it broadens the addressable population from the biomarker-defined dMMR/MSI-H subset to a much larger group of patients with primary advanced or recurrent endometrial cancer. Qualitatively, this widens the potential commercial opportunity, although actual uptake will depend on clinical adoption, competition, pricing and reimbursement.
GSK also cites the investigational rectal-cancer programme as a potential future opportunity. Dostarlimab received US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer on 16 December 2024, with the AZUR-1 registrational programme ongoing. This is investigational only and not approved anywhere; commercial performance will depend on trial outcomes and regulatory decisions that are not guaranteed.
How large is the addressable market?
Endometrial cancer is one of the more common gynaecological cancers, and the advanced or recurrent setting represents the pool of patients for whom systemic therapy is considered. The move from a biomarker-restricted combination indication to an all-comer combination indication is the principal lever expanding Jemperli's potential reach in this disease.
The size of the opportunity is best described qualitatively. No fabricated patient numbers, market-share or penetration figures are presented here. Realised demand will be shaped by treatment guidelines, the availability of competing regimens and health-technology assessment outcomes in individual markets.
In the UK, the National Institute for Health and Care Excellence has assessed dostarlimab with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer (TA1117), illustrating that reimbursement and access decisions, made separately from marketing authorisation, are a key determinant of real-world uptake. Similar assessments apply across other European markets.
What competitors does it face?
Jemperli operates in a competitive immuno-oncology landscape. The most direct competitor in frontline advanced or recurrent endometrial cancer is pembrolizumab (Keytruda, MSD/Merck), an anti-PD-1 antibody approved with chemotherapy in this setting, with lenvatinib for previously treated advanced disease, and as monotherapy for MSI-H/dMMR tumours including tissue-agnostic use.
Durvalumab (Imfinzi, AstraZeneca), an anti-PD-L1 antibody, is approved with carboplatin and paclitaxel for dMMR primary advanced or recurrent endometrial cancer, based on the DUO-E programme. Other checkpoint inhibitors, including nivolumab (Opdivo, Bristol Myers Squibb) and avelumab (Bavencio, Merck KGaA/Pfizer), also feature in the broader immuno-oncology field, with avelumab having been studied in endometrial cancer.
Competition is therefore intense, particularly in the first-line combination setting where multiple checkpoint-inhibitor-plus-chemotherapy regimens are available. Share of use in each market may depend on clinical data, guideline positioning, biomarker considerations, pricing and physician familiarity, rather than on any single factor.
What should investors monitor?
Several clinical and regulatory factors may warrant attention. The US tissue-agnostic dMMR solid-tumour indication was granted under accelerated approval and remains contingent on confirmatory trials; failure to verify clinical benefit could lead to withdrawal or restriction of that indication. Investors may also watch overall-survival and supporting data underpinning the all-comer combination indications, as any post-marketing safety signals or immune-related adverse events could affect labelling.
The investigational rectal-cancer opportunity is a potential catalyst but carries uncertainty: Breakthrough Therapy Designation and an ongoing registrational trial do not guarantee approval, and timing is unclear. Jurisdictional divergence is another consideration, as the EU and UK do not carry the US tissue-agnostic indication, limiting the geographic breadth of that particular use.
Standard pharmaceutical risks also apply, including eventual patent expiry and potential biosimilar competition over time, pricing and reimbursement pressure through bodies such as NICE and the Scottish Medicines Consortium, and the manufacturing and supply demands of a biologic. Readers may follow GSK's own financial disclosures for reported Jemperli turnover and its regulatory announcements for indication updates. Nothing here is a recommendation to buy, sell or hold any security, or to start, stop or change any medication.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...